Nachrichten zur Eli Lilly & Co. Aktie

Prediction: This Is What a $5,000 Investment in Eli Lilly Will Be Worth in 2031

Hint: Its a good idea to buy the stock today.…

Cholesterol drug setback casts doubt over multibillion-dollar race

Novartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer…

Heres Why Eli Lilly (LLY) Fell More Than Broader Market

The latest trading day saw Eli Lilly (LLY) settling at $1, representing a -2.21% change from its previous close.…

Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?

The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to…

Heres Why Eli Lilly (LLY) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

Eli Lilly’s $100B incretin opportunity: Is more upside coming?

Eli Lilly’s $100B incretin opportunity: Is more upside coming?…

Prediction: Heres What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years

Eli Lillys total return topped 367% over the past five years, largely thanks to enthusiasm for its GLP-1 offerings.…

Will Eli Lilly Split Its Stock? Heres What History Says Will Happen If It Does.

Fundamentals, not a stock split, will determine whether the bull case for Eli Lilly continues.…

Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal

LLYs $2.9B Merida deal adds immunology assets and expands its pipeline beyond obesity and diabetes into new growth areas.…

Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Heres What That Means for Investors.

Hardly for the first time recently, the company is making a pricey acquisition.…

Stocks making the biggest moves midday: PG&E, Edison International, Apple, Howmet Aerospace, Eli Lilly & more

These are some of the stocks posting the largest moves midday.…

Market movers: PG&E, Aon, Eli Lilly, BioVie...

…

Eli Lilly to buy Merida Biosciences for up to $2.88B, expanding immunology pipeline

Eli Lilly and Co (NYSE:LLY) said on Monday it will acquire privately held Merida Biosciences for up to $2.88 billion…

Should Eli Lilly Investors Be Worried About a Threat From Amylyx?

Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.…

Should Eli Lilly Investors Be Worried About a Threat From Amylyx?

Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.…

AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

Eli Lillys metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVies defensive dividend appeal.…

Eli Lilly: FDA-Zulassung für Mounjaro zur Herz-Kreislauf-Prävention eröffnet neue Milliardenmärkte

Mounjaro und Zepbound sorgten im 2. Quartal für ein Umsatzwachstum von 48 % auf 23,0 Mrd. USD. Die FDA-Zulassung…

Eli Lilly: Kostenvorteile bei Adipositas-Therapie für das Gesundheitssystem sichern Erstattungsperspektiven

Zepbound senkt bei Patienten ab 55 Jahren die monatlichen Kosten um bis zu 607 USD. Geringere Klinikaufenthalte decken die…

Lillys GLP-1 pill hits UK pharmacies as US battle with Novo intensifies

Eli Lillys weight-loss and diabetes pill goes on sale in UK pharmacies from Monday, giving patients an oral alternative to…

Eli Lilly launches oral weight-loss pill in UK pharmacies

Eli Lilly and Co (NYSE:LLY) has launched its once-daily weight-management and diabetes pill Foundayo in UK pharmacies, offering patients an…

Eli Lilly and Novo Nordisk Cant Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can

Could this little-known biotech be a hidden gem?…

Billionaire Ken Griffin Just Loaded Up on Eli Lilly Stock. Should You?

Griffins Q2 move is already paying off nicely.…

Eli Lilly: Shaking Off Competition From The Dethroned Novo Nordisk

…

Stock Split Watch: Is Eli Lilly (LLY) Stock Next?

Shares recently traded at $1,280 each, so a split wouldnt be surprising.…

There’s a Black Market for Eli Lilly’s Unapproved GLP-1 Drug. Here’s Why That’s Bullish

Can anyone challenge Eli Lilly in the weight loss space?…

Could Eli Lilly Be Worth More Than SpaceX by the End of 2026?

These two stocks both have market caps of more than $1 trillion, but Eli Lillys valuation is supported by strong…

Eli Lilly and J&J bounce on new data, as software stocks give up last weeks gains

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…

3 ‘Vital Stories’ Films Had World Premieres At Tribeca Festival

The Tribeca and Eli Lilly "Vital Stories" program at the Tribeca Film Festival premiered short films Reconstructing Charlie, Run It…

Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient

The companys peers in the pharmaceutical industry should be worried.…

GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)

They are way more than just GLP-1 stocks.…

ATOS: Multiple Catalysts Converge in 2H26

By David Bautz, PhDNASDAQ: ATOSREAD THE FULL ATOS RESEARCH REPORTBusiness UpdateAtossa Therapeutics, Inc. (NASDAQ: ATOS) is approaching a potentially important…

Eli Lillys GLP-1 Pricing Problem Is Actually a Growth Opportunity

The stock continues to look unstoppable.…

Can Novo Nordisks GLP-1 Pill Momentum Offset LLYs Growing Edge?

NVOs GLP-1 pills offer fresh momentum, but Eli Lillys fast-growing injectable and oral therapies threaten to widen the competitive gap.…

Lilly gains access to market that could add millions of customers

Eli Lilly (LLY) has spent 2026 defending its lead in the weight-loss drug market, mostly with injections. That approach is…

Novo Nordisk CEO defends lawsuit against Eli Lilly: Competition has to be fair

Novo Nordisk CEO defended the companys decision to sue rival Eli Lilly over its weight-loss drug advertising.…

Better Buy: Eli Lilly vs. Novo Nordisk

Novo Nordisk is playing catch-up in the GLP-1 race.…

UK green lights Lillys obesity pill

The British medicines ?regulator on Monday authorised Eli ?Lillys pill Foundayo for weight management and type 2 ?diabetes, ?becoming Europes…

Trotz gestrichener Milliarden: Eli-Lilly-Werk Alzey im Plan

ALZEY (dpa-AFX) - Der US-Pharmakonzern Eli Lilly will trotz der gestrichenen Milliardeninvestitionen die Produktionsstätte für Medikamente…

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

Its not much of a rivalry yet.…

BofA points to the Eli Lilly market that could outsize the U.S.

Eli Lilly (LLY) posted a second-quarter result strong enough to shift the debate around its stock. For months, the debate…

Eli Lillys Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem

Can anyone take the top spot away from Eli Lilly in the anti-obesity area?…

Eli Lilly: Fine Q2 2026 Results, But Alertness Required

…

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore…

Eli Lilly: GLP-1-Marktführer wächst mit Rekordquartal um 48 % - Aktie am Allzeithoch!

Das 2. Quartal überzeugt mit einem Umsatzwachstum von 48 %. Mounjaro und Zepbound liefern mit 14,9 Mrd. USD einen…

3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations

As investors look to balance growth opportunities with defensive positioning, Acadia Pharmaceuticals, CVS Health, and Eli Lilly stand out as…

Were increasing our Eli Lilly price target after another beat-and-raise quarter

The strength of its GLP-1 business suggests the stock still has more room to run.…

ROUNDUP 2/Starke Gewichtssenker: US-Pharmakonzern Lilly hebt erneut Umsatzziel

(Kurs aktualisiert) INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Lilly hebt nach einem starken…

ROUNDUP/Starke Gewichtssenker: US-Pharmakonzern Lilly hebt erneut Umsatzziel

INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Lilly hebt nach einem starken zweiten Quartal seine Prognose weiter…

Eli Lilly: Kapazitätsausbau und enorme Nachfrage nach GLP-1-Medikamenten prägen das 2. Quartal - Strategische Übernahmen sollen weiteres Wachstum sichern!

Eli Lilly profitiert massiv von der gigantischen Nachfrage nach Mounjaro und Zepbound, die Sättigungshormone nachahmen. Durch den Ausbau von…

KORREKTUR: US-Pharmakonzern Lilly hebt erneut Umsatzziel

(Korrigiert wird im letzten Satz die Erläuterung der Gewinnprognose. Diese wurde nur am oberen Ende gekürzt.) …